Skip to content

Citius Oncology, Inc. CTOR Other Income (Expense)

Other Income (Expense) at other companies

Delcath Systems logo
Delcath SystemsDCTH
-$58K-1,550%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$62K+27.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$6M-40.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$563M-760%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$4.04M-120%
Gilead Sciences logo
Gilead SciencesGILD
$235M+172%

Other financials

Income statement

See full
Revenue$1.7M
Gross profit$1.3M
Operating income-$28.6M-283%
Net income-$26.6M-244%
EPS (diluted)-$0.27-145%

Balance sheet

See full
Cash & equivalents$2.6M+2,350,466%
Total equity$35.3M-1.0%
Total assets$100.7M+10.1%

Cash flow

See full
Operating cash flow-$3.8M-179%

Valuation

See full
Market cap$60.45M-74.7%

Returns & leverage

See full
Return on equity-119.9%+46.7pp
Current ratio0.5×+0.1×

Where this comes from

Reported directly by Citius Oncology, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.

The official record: Citius Oncology, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Citius Oncology, Inc.'s other income (expense).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Citius Oncology, Inc.'s other income (expense)?
Citius Oncology, Inc. (CTOR) reported other income (expense) of $1.77M in Q1 2026.
How has Citius Oncology, Inc.'s other income (expense) changed year-over-year?
Citius Oncology, Inc.'s other income (expense) increased by 4003.3% year-over-year, from -$45.41K to $1.77M.
What does other income (expense) mean?
Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.